BNP Paribas Financial Markets Makes New Investment in CureVac (NASDAQ:CVAC)

BNP Paribas Financial Markets purchased a new position in shares of CureVac (NASDAQ:CVAC - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 171,682 shares of the company's stock, valued at approximately $585,000. BNP Paribas Financial Markets owned 0.08% of CureVac as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Alyeska Investment Group L.P. boosted its holdings in CureVac by 25.0% in the 4th quarter. Alyeska Investment Group L.P. now owns 500,000 shares of the company's stock valued at $1,705,000 after purchasing an additional 100,000 shares during the last quarter. Geode Capital Management LLC raised its position in shares of CureVac by 10.3% during the 4th quarter. Geode Capital Management LLC now owns 241,750 shares of the company's stock valued at $824,000 after buying an additional 22,491 shares during the period. Northern Trust Corp lifted its holdings in CureVac by 98.1% in the fourth quarter. Northern Trust Corp now owns 60,100 shares of the company's stock valued at $205,000 after acquiring an additional 29,759 shares during the last quarter. Quadrant Capital Group LLC lifted its holdings in CureVac by 61.8% in the fourth quarter. Quadrant Capital Group LLC now owns 50,016 shares of the company's stock valued at $171,000 after acquiring an additional 19,098 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its position in CureVac by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 47,568 shares of the company's stock worth $162,000 after acquiring an additional 4,425 shares during the period. Institutional investors and hedge funds own 17.26% of the company's stock.

CureVac Trading Up 4.3%

NASDAQ:CVAC traded up $0.19 during trading hours on Thursday, reaching $4.63. 1,142,731 shares of the stock were exchanged, compared to its average volume of 740,616. CureVac has a twelve month low of $2.37 and a twelve month high of $5.28. The business has a 50-day moving average of $3.35 and a two-hundred day moving average of $3.33. The company has a market capitalization of $1.04 billion, a price-to-earnings ratio of 8.42 and a beta of 2.43. The company has a quick ratio of 6.19, a current ratio of 6.20 and a debt-to-equity ratio of 0.05.

CureVac (NASDAQ:CVAC - Get Free Report) last announced its earnings results on Thursday, May 22nd. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.08). The firm had revenue of $0.94 million for the quarter, compared to analysts' expectations of $4.27 million. CureVac had a net margin of 20.72% and a return on equity of 21.98%. On average, equities analysts predict that CureVac will post 0.72 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. JMP Securities restated a "market outperform" rating and issued a $10.00 target price on shares of CureVac in a research report on Wednesday. UBS Group reduced their price objective on shares of CureVac from $13.00 to $12.00 and set a "buy" rating on the stock in a report on Wednesday, April 30th.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.